Fresh analysis indicates that patients who come off new GLP-1 drugs like Wegovy and Mounjaro may regain lost weight at a significantly accelerated pace than those who end conventional diet and exercise regimens.
Findings released in a leading health publication demonstrates that while obese people can lose about a fifth of their body weight while using the jabs, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals buying these treatments must be informed of the risk of rapid rebound weight gain when the treatment concludes," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery suggests a return to pre-treatment mass in about 18 months.
Comparing Therapies
The study, which looked at 37 of trials involving over 9,000 of participants, compared the effects of GLP-1 agonists with other pills.
The team note that people who shed pounds through diet and exercise generally experience a less rapid weight regain—around 0.1 kg a month—post-intervention.
The Reason for the Fast Rebound
Experts suggest the mechanism of the drugs explains the heightened rebound.
GLP-1 drugs copy a body's own chemical called GLP-1, which controls feelings of fullness.
"Artificially providing the hormone concentrations far above than normal might result in the system to generate a reduced amount of its own natural GLP-1, and may also diminish sensitivity to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this hormone supplement means hunger is uncontrolled, making overeating a significant risk."
An Ongoing Issue?
Health authorities suggest the jabs for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.
A number of clinicians contend that, given the high risk of relapse, the treatment should be considered life-long.
This view is reinforced by pharmaceutical companies, who state that the results "underscore the long-term character of excess weight," similar to managing conditions like hypertension.
Patient Experiences
Individuals who have stopped the jabs report a sudden return of appetite.
"It was like something flipping and you're instantly starving," recalled an individual.
This difficulty is compounded if patients have not developed lasting lifestyle or habit modifications during treatment.
Significant Use
Figures suggest that millions of people in the UK have used these injections in the past year, with desire being substantial.
- Use is more common among females than men.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
Finally, clinicians stress that while the jabs are powerful agents for shedding pounds, they are not a standalone solution and lasting health benefits hinges on integrated behavioural support.
